Developer docs
API playgroundTry for free, no card

Search company profiles

Osivax

Full company profile

uuid0000adc

Namestring
Osivax
Legal namestring
Osivax SAS
Websiteurl
osivax.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Osivax SAS is a privately held, clinical-stage biopharmaceutical company founded in 2017 and headquartered in Lyon, France, with operating subsidiaries in Liège, Belgium and Melbourne, Australia. The company develops universal vaccines targeting highly conserved internal antigens of mutating pathogens using its proprietary oligoDOM™ self-assembling nanoparticle platform, which is engineered to elicit potent CD8+ T-cell responses alongside B-cell immunity. Its lead candidate, OVX836, is a broad-spectrum influenza A vaccine that targets the nucleoprotein rather than the conventional hemagglutinin surface antigen; it has progressed through seven clinical trials involving more than 4,000 participants, with a Phase 2a study demonstrating 84% protection against PCR-confirmed symptomatic influenza (published in The Lancet Infectious Diseases, July 2023). The pipeline also includes OVX033, a universal sarbecovirus vaccine candidate, and PANHPVAX, a pan-strain HPV vaccine co-developed with DKFZ in Germany.

The company's business model rests on three pillars: non-dilutive grant funding from agencies such as BARDA ($19.5M, August 2025), NIAID ($1.5M+, December 2023), Bpifrance (€10M, June 2022), and the Bill & Melinda Gates Foundation; equity financing through a Series A round of €8M in July 2019 led by Noshaq and a Series B round of €10M in March 2025 with Meiji Seika Pharma; and regional licensing and commercialization partnerships, most notably an exclusive license option granted to KM Biologics (Meiji Group) for Japan in September 2024. Osivax currently has no commercial products and generates no product revenue; future distribution is planned through pharmaceutical licensees and government procurement channels. Customer segments are governments, global health agencies, and large pharmaceutical partners seeking differentiated vaccine assets for pandemic preparedness and seasonal influenza portfolios.

Short descriptiontext

Osivax is a clinical-stage French biopharmaceutical company developing universal vaccines against influenza, sarbecoviruses, and HPV using its proprietary oligoDOM™ self-assembling nanoparticle platform. It serves governments, global health agencies, and pharmaceutical partners through grants, equity financing, and regional licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
universal vaccine development, influenza vaccine research, nanoparticle vaccine platform, T-cell vaccine technology, clinical-stage biotechnology
Industry2 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAB
Adult Vaccines
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Vaccines
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Vaccine Product Sales
TypeOne Time License
Description

Osivax is developing a pipeline of universal influenza vaccines (OVX836, OVX033) intended for commercialization. The company aims to provide broad-spectrum protection against influenza and other mutating viruses through its proprietary vaccine candidates.

osivax.com
2Licensing and Partnership Agreements
TypeLicensing Royalties
Description

Osivax generates non-dilutive funding through licensing agreements with pharmaceutical partners such as KM Biologics for Japan rights, and collaborates with global health agencies and pharmaceutical companies for co-development and commercialization.

osivax.com
3Government and NGO Grants
TypeProfessional Services
Description

Osivax receives significant non-dilutive funding from government agencies (BARDA $19.5M, Bpifrance €10M, NIAID $1.5M+) and foundations (Bill & Melinda Gates Foundation) to support vaccine development programs.

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1oligoDOM
Description

Proprietary self-assembling nanoparticles platform technology designed to trigger potent T-cell responses and strong B-cell responses for universal vaccine development

osivax.com
+3 more records
Core offering1 text field

Osivax develops universal vaccine candidates using its proprietary oligoDOM™ self-assembling nanoparticle platform, which targets highly conserved internal antigens (nucleoprotein/nucleocapsid) to elicit potent T-cell and B-cell immune responses. Its lead candidates include OVX836 (broad-spectrum influenza A vaccine, Phase 2b), OVX033 (universal sarbecovirus vaccine, Phase 1 complete), and PANHPVAX (pan-strain HPV vaccine developed with DKFZ). The company is currently clinical-stage and pre-commercial, with future distribution planned through regional pharmaceutical licensing and government procurement channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 84% protection against PCR-confirmed symptomatic influenza compared to placebo in Phase 2a trial
+3 more records
Product overview1 text field

Osivax is a clinical-stage biopharmaceutical company developing a portfolio of universal vaccines leveraging its proprietary oligoDOM™ self-assembling nanoparticle platform technology. The company's core product pipeline includes OVX836 (a universal influenza A vaccine targeting the nucleoprotein), OVX033 (a universal sarbecovirus vaccine targeting the nucleocapsid), and PANHPVAX (a pan-strain HPV vaccine developed with dkfz). Osivax combines its T-cell vaccine technology with traditional antibody-based vaccines to develop next-generation vaccines that empower both arms of the immune system. The company is focused on providing broad-spectrum protection against constantly mutating pathogens, starting with influenza while expanding to other infectious diseases.

Product and service4 records
1OVX836
CategoryVaccines - Influenza
Description

OVX836 is a first-in-class broad-spectrum influenza A vaccine candidate that targets the nucleoprotein (NP), a highly conserved internal antigen. Using Osivax's proprietary oligoDOM™ technology, OVX836 self-assembles into nanoparticles that trigger powerful T-cell and B-cell immune responses, providing broader protection against current and future influenza strains. The vaccine candidate is in Phase 2b clinical development with over 4,000 participants tested across 7 clinical trials to date.

2OVX033
CategoryVaccines - Coronavirus
Description

OVX033 is a universal sarbecovirus vaccine candidate that targets the nucleocapsid protein, an internal and invariant antigen. Leveraging the oligoDOM™ technology platform, OVX033 is designed to provide broad-spectrum protection against all current and future sarbecoviruses, including SARS-CoV-2 variants. Phase 1 trial completed enrollment in June 2024.

3oligoDOM™ Technology Platform
CategoryVaccine Technology Platform
Description

oligoDOM™ is Osivax's proprietary self-assembling nanoparticle technology platform specifically designed to trigger potent T-cell responses in addition to strong and sustained B-cell responses. The technology transforms small, non-immunogenic native antigens into large nanoparticles that are easily detected by the immune system, enabling development of universal vaccines against conserved internal antigens. The platform is licensed for use in the PANHPVAX HPV vaccine candidate developed with DKFZ.

4PANHPVAX
CategoryVaccines - HPV
Description

PANHPVAX is a pan-strain human papillomavirus vaccine candidate developed by DKFZ using Osivax's oligoDOM™ technology platform. The vaccine aims to provide protection against almost all carcinogenic HPV types. It is being co-developed under a licensing partnership between Osivax and DKFZ.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Partnership to advance T-cell immunity using CEPI's World-First Adjuvant Library. Osivax will access CEPI's adjuvant library to investigate whether an adjuvanted formulation of OVX836 could enable dose-sparing in pandemic response contexts, potentially maximizing vaccine supply and accelerating access at scale.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-08-26
Description

$19.5 million award to advance next-generation influenza vaccine OVX836 for pandemic and seasonal preparedness. BARDA funding supports broad-spectrum influenza A vaccine development targeting conserved internal antigens.

3KM Biologics
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-09-10
Description

Exclusive license option agreement for broad-spectrum universal influenza vaccine in Japan. KM Biologics is a Meiji Group company. Agreement provides regional commercialization rights.

osivax.com
4Vaccine Clinical Investigator Center Cochin-Pasteur, APHP
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-15
Description

First-In-Human trial for sarbecovirus vaccine candidate OVX033 conducted at this clinical site.

osivax.com
5NIAID (National Institute of Allergy and Infectious Diseases)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-05
Description

Over USD 1.5 million grant to support preclinical studies of OVX836 against pandemic influenza strains (H1N1 and H5N1). Studies conducted at CEA in France to evaluate vaccine effectiveness.

osivax.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-28
Description

Grant to fund research and development of OVX836, evaluating vaccine efficacy against various influenza strains and potential for long-term protection. Ongoing clinical trials in Belgium and Australia.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-22
Description

€10 million grant to support clinical development of OVX836, a broad-spectrum flu vaccine. Funding used for Phase 2b clinical trial to evaluate vaccine effectiveness against various flu strains.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-12-05
Description

Agreement with US National Institutes of Health for preclinical services including refined immunological assessments of OVX836 using flow cytometry analyses to characterize CD4, CD8 and polyfunctionality of T cell immune responses.

Strategic tierCoreTypeTechnology or Integration
Description

Research partnership for preclinical evaluation of OVX836 vaccine candidate against pandemic influenza strains. CEA conducts vaccine effectiveness studies in France.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for pan-strain human papillomavirus vaccine (PANHPVAX) development using Osivax's oligoDOM™ technology platform. Second license agreement signed April 2018 for clinical development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial partnership for Phase 1 and Phase 2a studies of OVX836. CEV is a WHO Collaborating Centre for control and prevention of infectious diseases, founded by Prof. Pierre Van Damme.

12CEVAC - Center for Vaccinology, Ghent University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial partnership under Principal Investigator Prof. Isabel Leroux-Roels for Phase 2a and Phase 2b trials. Large track record in conducting vaccine trials for numerous infectious diseases.

osivax.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1BiondVax Pharmaceuticals
TypeDirect peer
Description

Israeli clinical-stage biotech developing M-001, a universal influenza vaccine candidate targeting conserved epitopes. Closest direct competitor in the universal flu vaccine space; serves as a cautionary tale after Phase 3 failure despite multiple Phase 2 successes.

TypeBroad incumbent
Description

Major mRNA vaccine company developing mRNA-1010 and follow-on mRNA influenza vaccine programs with strain-agnostic claims. Represents the most significant competitive threat to oligoDOM™ positioning and is the benchmark for influenza vaccine platform valuations.

3Sanofi Pasteur
TypeBroad incumbent
Description

World's largest influenza vaccine manufacturer (Fluzone HD, Flublok), also partnered with Translate Bio on mRNA flu vaccines. Represents the dominant incumbent that any new universal flu entrant must displace or partner with.

TypeBroad incumbent
Description

Major global influenza vaccine manufacturer (Fluad, Flucelvax) with cell-based and adjuvanted platforms. Comparable to Osivax as a leading flu vaccine innovator with established global commercial infrastructure.

TypeBroad incumbent
Description

Top-tier global vaccine manufacturer with multiple influenza vaccine franchises (Fluarix, Flulaval) and deep expertise in vaccine adjuvant systems. Likely large-pharma partner or acquirer candidate for Osivax given management pedigree.

TypeEmerging player
Description

Clinical-stage vaccine company using nanoparticle technology (Matrix-M adjuvant, recombinant protein nanoparticles) for influenza and COVID vaccines. Most relevant peer from a nanoparticle platform architecture perspective.

TypeDirect peer
Description

US clinical-stage biotech developing M2SR, a universal influenza vaccine candidate based on live-attenuated single-replication virus. Direct competitor targeting broad influenza protection via conserved antigens.

TypeEmerging player
Description

Clinical-stage biotech using enveloped virus-like particle (eVLP) platform technology for infectious disease and oncology vaccines. Comparable platform-technology peer with multiple vaccine candidates.

TypeBroad incumbent
Description

Major mRNA vaccine company with influenza programs and established Pfizer partnership. Represents both a competitive threat (mRNA flu) and a potential partnership/acquisition target given European geographic overlap with Osivax.

TypeEmerging player
Description

European-headquartered mRNA vaccine company with broad infectious disease pipeline including influenza and coronavirus programs. Comparable European biotech with platform-technology vaccine approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Osivax

Biopharmaceutical Vaccinesosivax.com

Osivax is a clinical-stage French biopharmaceutical company developing universal vaccines against influenza, sarbecoviruses, and HPV using its proprietary oligoDOM™ self-assembling nanoparticle platform. It serves governments, global health agencies, and pharmaceutical partners through grants, equity financing, and regional licensing.

What Osivax does

Osivax SAS is a privately held, clinical-stage biopharmaceutical company founded in 2017 and headquartered in Lyon, France, with operating subsidiaries in Liège, Belgium and Melbourne, Australia. The company develops universal vaccines targeting highly conserved internal antigens of mutating pathogens using its proprietary oligoDOM™ self-assembling nanoparticle platform, which is engineered to elicit potent CD8+ T-cell responses alongside B-cell immunity. Its lead candidate, OVX836, is a broad-spectrum influenza A vaccine that targets the nucleoprotein rather than the conventional hemagglutinin surface antigen; it has progressed through seven clinical trials involving more than 4,000 participants, with a Phase 2a study demonstrating 84% protection against PCR-confirmed symptomatic influenza (published in The Lancet Infectious Diseases, July 2023). The pipeline also includes OVX033, a universal sarbecovirus vaccine candidate, and PANHPVAX, a pan-strain HPV vaccine co-developed with DKFZ in Germany.

The company's business model rests on three pillars: non-dilutive grant funding from agencies such as BARDA ($19.5M, August 2025), NIAID ($1.5M+, December 2023), Bpifrance (€10M, June 2022), and the Bill & Melinda Gates Foundation; equity financing through a Series A round of €8M in July 2019 led by Noshaq and a Series B round of €10M in March 2025 with Meiji Seika Pharma; and regional licensing and commercialization partnerships, most notably an exclusive license option granted to KM Biologics (Meiji Group) for Japan in September 2024. Osivax currently has no commercial products and generates no product revenue; future distribution is planned through pharmaceutical licensees and government procurement channels. Customer segments are governments, global health agencies, and large pharmaceutical partners seeking differentiated vaccine assets for pandemic preparedness and seasonal influenza portfolios.

Osivax firmographics

Firmographics
Name
Osivax
Legal name
Osivax SAS
Website
https://osivax.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Osivax is a clinical-stage French biopharmaceutical company developing universal vaccines against influenza, sarbecoviruses, and HPV using its proprietary oligoDOM™ self-assembling nanoparticle platform. It serves governments, global health agencies, and pharmaceutical partners through grants, equity financing, and regional licensing.
Ownership category
akta.pro rank

Osivax industry classification

Industry
Product category
Biopharmaceutical Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAB
Adult Vaccines

Keywords

  • Universal vaccine development
  • Influenza vaccine research
  • Nanoparticle vaccine platform
  • T-cell vaccine technology
  • Clinical-stage biotechnology

Where Osivax is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices4 records

Markets served

Osivax business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Vaccine Product Sales: Osivax is developing a pipeline of universal influenza vaccines (OVX836, OVX033) intended for commercialization. The company aims to provide broad-spectrum protection against influenza and other mutating viruses through its proprietary vaccine candidates.
  2. Licensing and Partnership Agreements: Osivax generates non-dilutive funding through licensing agreements with pharmaceutical partners such as KM Biologics for Japan rights, and collaborates with global health agencies and pharmaceutical companies for co-development and commercialization.
  3. Government and NGO Grants: Osivax receives significant non-dilutive funding from government agencies (BARDA $19.5M, Bpifrance €10M, NIAID $1.5M+) and foundations (Bill & Melinda Gates Foundation) to support vaccine development programs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Osivax product offering

Product offering

Core offering

Osivax develops universal vaccine candidates using its proprietary oligoDOM™ self-assembling nanoparticle platform, which targets highly conserved internal antigens (nucleoprotein/nucleocapsid) to elicit potent T-cell and B-cell immune responses. Its lead candidates include OVX836 (broad-spectrum influenza A vaccine, Phase 2b), OVX033 (universal sarbecovirus vaccine, Phase 1 complete), and PANHPVAX (pan-strain HPV vaccine developed with DKFZ). The company is currently clinical-stage and pre-commercial, with future distribution planned through regional pharmaceutical licensing and government procurement channels.

Product overview

Osivax is a clinical-stage biopharmaceutical company developing a portfolio of universal vaccines leveraging its proprietary oligoDOM™ self-assembling nanoparticle platform technology. The company's core product pipeline includes OVX836 (a universal influenza A vaccine targeting the nucleoprotein), OVX033 (a universal sarbecovirus vaccine targeting the nucleocapsid), and PANHPVAX (a pan-strain HPV vaccine developed with dkfz). Osivax combines its T-cell vaccine technology with traditional antibody-based vaccines to develop next-generation vaccines that empower both arms of the immune system. The company is focused on providing broad-spectrum protection against constantly mutating pathogens, starting with influenza while expanding to other infectious diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • oligoDOM: Proprietary self-assembling nanoparticles platform technology designed to trigger potent T-cell responses and strong B-cell responses for universal vaccine development
  • OVX836
  • OVX033
  • Asuniva

Products and services

  • OVX836 OVX836 is a first-in-class broad-spectrum influenza A vaccine candidate that targets the nucleoprotein (NP), a highly conserved internal antigen. Using Osivax's proprietary oligoDOM™ technology, OVX836 self-assembles into nanoparticles that trigger powerful T-cell and B-cell immune responses, providing broader protection against current and future influenza strains. The vaccine candidate is in Phase 2b clinical development with over 4,000 participants tested across 7 clinical trials to date.
  • OVX033 OVX033 is a universal sarbecovirus vaccine candidate that targets the nucleocapsid protein, an internal and invariant antigen. Leveraging the oligoDOM™ technology platform, OVX033 is designed to provide broad-spectrum protection against all current and future sarbecoviruses, including SARS-CoV-2 variants. Phase 1 trial completed enrollment in June 2024.
  • oligoDOM™ Technology Platform oligoDOM™ is Osivax's proprietary self-assembling nanoparticle technology platform specifically designed to trigger potent T-cell responses in addition to strong and sustained B-cell responses. The technology transforms small, non-immunogenic native antigens into large nanoparticles that are easily detected by the immune system, enabling development of universal vaccines against conserved internal antigens. The platform is licensed for use in the PANHPVAX HPV vaccine candidate developed with DKFZ.
  • PANHPVAX PANHPVAX is a pan-strain human papillomavirus vaccine candidate developed by DKFZ using Osivax's oligoDOM™ technology platform. The vaccine aims to provide protection against almost all carcinogenic HPV types. It is being co-developed under a licensing partnership between Osivax and DKFZ.

Quantifiable outcome

  • 84% protection against PCR-confirmed symptomatic influenza compared to placebo in Phase 2a trial
  • +3 more outcomes

Companies that use Osivax

Customer profile

Segments3 records

Ideal customer profiles3 records

Osivax technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Osivax partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and flagship.

  • CEPI (Coalition for Epidemic Preparedness Innovations)coreStrategic or Co-development Partner · 7 April 2026Partnership to advance T-cell immunity using CEPI's World-First Adjuvant Library. Osivax will access CEPI's adjuvant library to investigate whether an adjuvanted formulation of OVX836 could enable dose-sparing in pandemic response contexts, potentially maximizing vaccine supply and accelerating access at scale.
  • BARDA (Biomedical Advanced Research and Development Authority)flagshipStrategic or Co-development Partner · 26 August 2025$19.5 million award to advance next-generation influenza vaccine OVX836 for pandemic and seasonal preparedness. BARDA funding supports broad-spectrum influenza A vaccine development targeting conserved internal antigens.
  • KM BiologicsflagshipOEM/ Whitelabel/ Licensing Partner · 10 September 2024Exclusive license option agreement for broad-spectrum universal influenza vaccine in Japan. KM Biologics is a Meiji Group company. Agreement provides regional commercialization rights.
  • Vaccine Clinical Investigator Center Cochin-Pasteur, APHPcoreStrategic or Co-development Partner · 15 February 2024First-In-Human trial for sarbecovirus vaccine candidate OVX033 conducted at this clinical site.
  • NIAID (National Institute of Allergy and Infectious Diseases)coreStrategic or Co-development Partner · 5 December 2023Over USD 1.5 million grant to support preclinical studies of OVX836 against pandemic influenza strains (H1N1 and H5N1). Studies conducted at CEA in France to evaluate vaccine effectiveness.
  • Bill & Melinda Gates FoundationcoreStrategic or Co-development Partner · 28 March 2023Grant to fund research and development of OVX836, evaluating vaccine efficacy against various influenza strains and potential for long-term protection. Ongoing clinical trials in Belgium and Australia.
  • BpifrancecoreStrategic or Co-development Partner · 22 June 2022€10 million grant to support clinical development of OVX836, a broad-spectrum flu vaccine. Funding used for Phase 2b clinical trial to evaluate vaccine effectiveness against various flu strains.
  • NIH/NIAIDcoreStrategic or Co-development Partner · 5 December 2019Agreement with US National Institutes of Health for preclinical services including refined immunological assessments of OVX836 using flow cytometry analyses to characterize CD4, CD8 and polyfunctionality of T cell immune responses.
  • CEA (French Alternative Energies and Atomic Energy Commission)coreTechnology or IntegrationResearch partnership for preclinical evaluation of OVX836 vaccine candidate against pandemic influenza strains. CEA conducts vaccine effectiveness studies in France.
  • DKFZ (German Cancer Research Center)coreStrategic or Co-development PartnerCollaboration for pan-strain human papillomavirus vaccine (PANHPVAX) development using Osivax's oligoDOM™ technology platform. Second license agreement signed April 2018 for clinical development.
  • University of Antwerp - Center for the Evaluation of Vaccination (CEV)coreStrategic or Co-development PartnerClinical trial partnership for Phase 1 and Phase 2a studies of OVX836. CEV is a WHO Collaborating Centre for control and prevention of infectious diseases, founded by Prof. Pierre Van Damme.
  • CEVAC - Center for Vaccinology, Ghent UniversitycoreStrategic or Co-development PartnerClinical trial partnership under Principal Investigator Prof. Isabel Leroux-Roels for Phase 2a and Phase 2b trials. Large track record in conducting vaccine trials for numerous infectious diseases.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Osivax competitors and assessment

Company assessment

Direct peers

  • BiondVax Pharmaceuticals: Israeli clinical-stage biotech developing M-001, a universal influenza vaccine candidate targeting conserved epitopes. Closest direct competitor in the universal flu vaccine space; serves as a cautionary tale after Phase 3 failure despite multiple Phase 2 successes.
  • FluGen: US clinical-stage biotech developing M2SR, a universal influenza vaccine candidate based on live-attenuated single-replication virus. Direct competitor targeting broad influenza protection via conserved antigens.

Broad incumbents

  • Moderna: Major mRNA vaccine company developing mRNA-1010 and follow-on mRNA influenza vaccine programs with strain-agnostic claims. Represents the most significant competitive threat to oligoDOM™ positioning and is the benchmark for influenza vaccine platform valuations.
  • Sanofi Pasteur: World's largest influenza vaccine manufacturer (Fluzone HD, Flublok), also partnered with Translate Bio on mRNA flu vaccines. Represents the dominant incumbent that any new universal flu entrant must displace or partner with.
  • CSL Seqirus: Major global influenza vaccine manufacturer (Fluad, Flucelvax) with cell-based and adjuvanted platforms. Comparable to Osivax as a leading flu vaccine innovator with established global commercial infrastructure.
  • GSK: Top-tier global vaccine manufacturer with multiple influenza vaccine franchises (Fluarix, Flulaval) and deep expertise in vaccine adjuvant systems. Likely large-pharma partner or acquirer candidate for Osivax given management pedigree.
  • BioNTech: Major mRNA vaccine company with influenza programs and established Pfizer partnership. Represents both a competitive threat (mRNA flu) and a potential partnership/acquisition target given European geographic overlap with Osivax.

Emerging players

  • Novavax: Clinical-stage vaccine company using nanoparticle technology (Matrix-M adjuvant, recombinant protein nanoparticles) for influenza and COVID vaccines. Most relevant peer from a nanoparticle platform architecture perspective.
  • VBI Vaccines: Clinical-stage biotech using enveloped virus-like particle (eVLP) platform technology for infectious disease and oncology vaccines. Comparable platform-technology peer with multiple vaccine candidates.
  • CureVac: European-headquartered mRNA vaccine company with broad infectious disease pipeline including influenza and coronavirus programs. Comparable European biotech with platform-technology vaccine approach.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Osivax social profiles

Digital presence

Osivax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Osivax leadership team

Management profile

Number of profiles

Profiles9 records

Osivax subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Osivax funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Osivax M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osivax

What does Osivax do?

Osivax develops universal vaccine candidates using its proprietary oligoDOM™ self-assembling nanoparticle platform, which targets highly conserved internal antigens (nucleoprotein/nucleocapsid) to elicit potent T-cell and B-cell immune responses. Its lead candidates include OVX836 (broad-spectrum influenza A vaccine, Phase 2b), OVX033 (universal sarbecovirus vaccine, Phase 1 complete), and PANHPVAX (pan-strain HPV vaccine developed with DKFZ). The company is currently clinical-stage and pre-commercial, with future distribution planned through regional pharmaceutical licensing and government procurement channels.

Is Osivax a public or private company?

Osivax is a private company. It is classified as venture growth investor backed and is currently operating.

When was Osivax founded?

Osivax was founded in 2017. It employs 51 to 100 people.

Where is Osivax based?

Osivax is headquartered in Lyon, France, in the Europe region.

How does Osivax make money?

Three revenue lines are on record. Vaccine Product Sales are the primary driver. The others are licensing and Partnership Agreements and government and NGO Grants.

Who are Osivax's main competitors?

Direct peers on record are BiondVax Pharmaceuticals and FluGen. Broad incumbents are Moderna, Sanofi Pasteur, CSL Seqirus, GSK and BioNTech. Emerging players are Novavax, VBI Vaccines and CureVac.

Does Osivax have an API?

No public API is recorded for Osivax.

What industry is Osivax in?

Osivax's product category is Biopharmaceutical Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAIAEAB, Adult Vaccines. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Endpoints NewsOsivax pivots to combo approach after flu jab fails in Phase 2bOsivax's lead flu vaccine failed in a Phase 2b trial, but the French biotech plans to pivot to a combination approach. The company still holds out hope for the program.The Pharma LetterOsivax’s universal flu vaccine fails in Phase IIb, pivots to combination approachOsivax's Phase IIb trial of its nucleoprotein-based influenza A vaccine OVX836 failed to meet the prespecified 50% efficacy endpoint. The trial of 2,850 adults in four European countries showed a 24% point estimate, not statistically significant. The company will now develop the candidate in combination with conventional seasonal flu vaccines.GlobeNewswireOsivax Reports Phase 2b Results for OVX836 and Advances Combination Strategy for Next-Generation Seasonal Influenza VaccinesOsivax reported Phase 2b results for OVX836, a nucleoprotein-based influenza vaccine, in 2,850 European adults. The trial did not meet its primary endpoint of 50% efficacy, but showed a 24% point estimate and consistent signals across influenza A subtypes. The company plans combination vaccines with GC Biopharma and an undisclosed partner, with a first Phase 1/2 study expected in Q4 2027.FierceBiotechOsivax focuses on combo strategy for flu vaccine after phase 2 failOsivax's influenza vaccine OVX836 failed a phase 2b study, showing only 24% efficacy versus the 50% required. The company will now pursue a combination with GC Biopharma's seasonal flu vaccine, based on earlier evidence of synergistic protection.PharmExecOsivax And GC Biopharma Enter Collaboration to Develop Next Generation Influenza VaccineOsivax and GC Biopharma announced a long-term collaboration to develop and commercialize a combination seasonal influenza vaccine combining Osivax's Ovx836, a broad-spectrum influenza A candidate targeting the conserved nucleoprotein, with GC Biopharma's WHO-prequalified Gc flu. Osivax leads global development and commercialization outside Korea, where GC Biopharma retains exclusive rights, with undisclosed financial terms.BusinesskoreaGC Green Cross has begun joint development of a next-generation influenza vaccine with French company Osivax.GC Green Cross has started joint development of a next-generation influenza vaccine with French company Osivax. CEO Heo Eun-cheol said the collaboration aims to overcome limitations of existing seasonal flu prevention, while Osivax CEO Alexandre Le Ber noted the combined technologies and production capabilities will underpin the vaccine's development. No financial terms were disclosed.AInvestOsivax and GC Biopharma: The Flu-Vaccine Deal That Is a Map of the WorldOsivax, a private French biotech, and GC Biopharma, a South Korean drugmaker, announced on August 27 a collaboration combining Osivax's nucleoprotein-targeting OVX836 with GC's seasonal flu vaccine GC FLU. Osivax gets a non-exclusive, sublicensable global license excluding Japan and South Korea, while GC retains exclusive rights in Korea and supplies the antibody component. Financial terms were not disclosed.FierceBiotechOsivax bags flu vaccine rights to pursue combination shot visionFrench biotech Osivax has licensed GC Biopharma's inactivated seasonal influenza vaccine, GC FLU, outside Japan and Korea, to develop a combination shot pairing its nucleoprotein-targeting candidate OVX836 with GC FLU. Osivax will handle development and commercialization outside Korea, while GC Biopharma supplies the vaccine and receives royalties. The company cited early phase 2a and phase 2 data suggesting broader cross-protection.YahooOsivax and GC Biopharma Enter Strategic Collaboration to Develop a Next-Generation Influenza Vaccine Combining OVX836 and GC FLUOsivax and GC Biopharma announced a long-term collaboration on 27 August 2026 to develop and commercialize a next-generation seasonal influenza vaccine combining Osivax's OVX836 T-cell vaccine with GC Biopharma's WHO-prequalified GC FLU inactivated vaccine. Osivax leads global development and commercialization outside Korea, where GC Biopharma retains exclusive rights and will supply GC FLU. Financial terms were not disclosed.European BiotechnologyOsivax and GC Biopharma partner on broader flu vaccineOsivax and GC Biopharma partnered to develop a seasonal influenza vaccine combining Osivax's OVX836 candidate with GC Biopharma's GC FLU vaccine. Osivax will lead development and commercialize outside South Korea and Japan, while GC Biopharma supplies GC FLU and retains rights in its home market. Financial terms were not disclosed.